{
  "id": 20383971,
  "title": "Why Indian drugmakers are losing pricing power in the US",
  "url": "https://urgent.news/2026/11/17/why-indian-drugmakers-are-losing-pricing-power-in-the-us",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T05:00:07.000Z",
  "source": {
    "name": "Live Mint",
    "slug": "live-mint",
    "url": "https://www.livemint.com/news/indian-pharmaceutical-companies-us-generics-market-drug-exports-pricing-pressure-generic-revlimid-lenalidomide-11794858396268.html"
  },
  "original_language": "en",
  "account": "Indian pharmaceutical companies are witnessing a decline in their pricing power within the United States, their most significant market. This decline is attributed to concentration among buyers and heightened competition, which has led to a reduction in sales and margins. In the July-September 2026 quarter, Cipla's North American revenue experienced a 19% decrease in rupee terms, primarily due to a decline in the sales of its generic Revlimid, a medication used to treat blood cancer. Revlimid also impacted Dr. Reddy's North American sales, while Lupin's sales in the United States declined by 13% from the April-June quarter after losing exclusivity on Tolvaptan and Mirabegron.",
  "summary": "Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue.",
  "key_points": [
    "Indian drugmakers see pricing power decline in US market.",
    "Cipla's Revlimid sales drop 19% in Q3 2026, impacting margins.",
    "Dr. Reddy's and Lupin also face US sales declines due to competition."
  ],
  "editors_take": "Increased buyer concentration and intense competition in the United States are eroding profit margins for Indian generic manufacturers as key product exclusivity periods expire.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}